BAYER AG
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 200
- Registration Number
- NCT06137170
- Locations
- 🇪🇸
Many Locations, Multiple Locations, Spain
A Study to Learn More About the Safety and the Level of BAY 1747846 in Body Given as Injection Into the Vein at Increasing Single Doses in Japanese Healthy Male Participants
- Conditions
- Interventions
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 25
- Registration Number
- NCT06125366
- Locations
- 🇯🇵
SOUSEIKAI Fukuoka Mirai Hospital, Fukuoka, Japan
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 300
- Registration Number
- NCT06117891
- Locations
- 🇺🇸
Mercy Medical Center - Medline Healthcare Services LLC, Baltimore, Maryland, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause
- Conditions
- Interventions
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 110
- Registration Number
- NCT06112756
- Locations
- 🇩🇪
Siteworks - Zentrum für klinische Studien Hannover, Hannover, Niedersachsen, Germany
🇺🇸MomDoc Women's Health Research | Scottsdale, AZ, Scottsdale, Arizona, United States
🇺🇸Preferred Research Partners, Little Rock, Arkansas, United States
An Observational Study to Learn More About the Impact of Gadoxetate Sodium-Enhanced Magnetic Resonance Imaging (EOB-MRI) When Used to Diagnose the Spread of Cancer From the Pancreas to the Liver in Japanese People Under Real-World Conditions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 39624
- Registration Number
- NCT06106568
- Locations
- 🇯🇵
Many locations, Multiple Locations, Japan
The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2500
- Registration Number
- NCT06075147
- Locations
- 🇬🇧
Many Locations, Multiple Locations, United Kingdom
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
- Conditions
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 4
- Registration Number
- NCT06053749
- Locations
- 🇸🇪
Many locations, Multiple Locations, Sweden
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Men With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Conditions
- Interventions
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 232
- Registration Number
- NCT06052306
- Locations
- 🇨🇦
Juravinski Cancer Centre - Clinical Trials Department, Hamilton, Ontario, Canada
🇨🇦Centre Hospitalier de l'Universite de Montreal (CHUM) - Hopi, Montreal, Quebec, Canada
🇨🇦McGill University Health Centre - Glen Site, Montreal, Quebec, Canada
A Study to Learn How Safe the Study Treatment BAY2701250 is, How it Affects the Body and How it Moves Into, Through and Out of the Body in Healthy Male Participants When a Single Amount is Given as an Injection Into the Vein (Intravenous Infusion) or Under the Skin (Subcutaneous Injection)
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 90
- Registration Number
- NCT06048120
- Locations
- 🇩🇪
NUVISAN GmbH Neu-Ulm, Neu-Ulm, Bayern, Germany
An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States
- Conditions
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2326
- Registration Number
- NCT06029010
- Locations
- 🇺🇸
Many Locations, Multiple Locations, New Jersey, United States